Weekly Topotecan Therapy in Patients With Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00194935

Recruitment Status : Terminated

First Posted : September 19, 2005

Last Update Posted : September 13, 2006

Sponsor:

Information provided by:

Weill Medical College of Cornell University

Study Description

Brief Summary:

The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

Condition or disease	Intervention/treatment	Phase
Ovarian Cancer	Drug: Topotecan	Phase 2

Detailed Description:

Patients with Stage IIIC and IV optimally-debulked ovarian cancer will be treated with 6 cycles (every 3 weeks) of carboplatin (AUC 5) and paclitaxel (175 mg/m2). Patients who demonstrate a complete clinical response to this regimen will then be treated with topotecan consolidation (4 mg/m2 weekly x 8 weeks for one cycle followed by a break in the 9th week) for a maximum of 3 cycles. Primary endpoints will be toxicity and the determination of the appropriate dose, schedule, and duration of topotecan for further consolidation trials.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Enrollment :	32 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase II Trial of Weekly Topotecan As Consolidation Therapy in Ovarian Cancer Patients After Initial Chemotherapy
Study Start Date :	February 2003
Study Completion Date :	August 2006

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Ovarian cancer

MedlinePlus related topics: Ovarian Cancer

Drug Information available for: Topotecan hydrochloride Topotecan

Genetic and Rare Diseases Information Center resources: Ovarian Cancer Ovarian Epithelial Cancer

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

The objective of this study is to evaluate the safety and feasibility of weekly topotecan consolidation therapy in patients with epithelial ovarian cancer.

Secondary Outcome Measures :

To determine the efficacy (Progression free survival) of weekly topotecan as consolidation therapy in ovarian cancer patients who are clinically NED or have microscopic disease only after first-line chemotherapy.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must have a histopathologic diagnosis of epithelial ovarian cancer.
Patients must have completed front-line chemotherapy and be clinically NED (CA 125 <35, negative CT scan, negative physical exam).
Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative).
Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy.
Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy.
Patients may have had only one prior chemotherapy regimen.

Exclusion Criteria:

Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer.
Patients who are pregnant or breast-feeding.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00194935

Locations

Layout table for location information

United States, New York
Weill Medcial College of Cornell University
New York, New York, United States, 10021

Sponsors and Collaborators

Weill Medical College of Cornell University

Investigators

Layout table for investigator information

Principal Investigator:	Thomas Caputo, M.D.	Weill Medical College of Cornell University

More Information

Layout table for additonal information

ClinicalTrials.gov Identifier:	NCT00194935
Other Study ID Numbers:	0103-636
First Posted:	September 19, 2005 Key Record Dates
Last Update Posted:	September 13, 2006
Last Verified:	September 2006

Keywords provided by Weill Medical College of Cornell University:


Ovarian Cancer Cancer of the Ovary

Additional relevant MeSH terms:

Layout table for MeSH terms

Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases	Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Topotecan Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents

To Top